menu
    • menu
    [{"orgOrder":0,"company":"Breast International Group","sponsor":"Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Breast International Group \/ Breast International Group","highestDevelopmentStatusID":"10","companyTruncated":"Breast International Group \/ Breast International Group"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Amcenestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breast International Group \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Breast International Group \/ Sanofi"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Breast International Group \/ Breast International Group","highestDevelopmentStatusID":"7","companyTruncated":"Breast International Group \/ Breast International Group"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Breast International Group \/ Breast International Group","highestDevelopmentStatusID":"8","companyTruncated":"Breast International Group \/ Breast International Group"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Breast International Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Immune-Attractant","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breast International Group \/ Breast International Group","highestDevelopmentStatusID":"8","companyTruncated":"Breast International Group \/ Breast International Group"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lucitanib","moa":"Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Breast International Group \/ Breast International Group","highestDevelopmentStatusID":"8","companyTruncated":"Breast International Group \/ Breast International Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Breast International Group

    Menu

    Breast International Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amcenestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi Partnering with Leading Academic Cooperative Groups to Study Amcenestrant in the Adjuvant Setting

                            Details : Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s amcenestrant in ER+ patients who prematurely discontinue ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 04, 2021

                            Lead Product(s) : Amcenestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune-Attractant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : UNICANCER

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractan...

                            Details : Immune-Attractant is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 20, 2016

                            Lead Product(s) : Immune-Attractant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : UNICANCER

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

                            Details : Palbociclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2015

                            Lead Product(s) : Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

                            Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 02, 2014

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucitanib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Servier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (...

                            Details : Lucitanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2014

                            Lead Product(s) : Lucitanib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Servier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed

                            Breast International Group

                            Belgium arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

                            Details : Nab-Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 10, 2012

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : ETOP IBCSG Partners Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth